Chromogenic and fluorescent in situ hybridization in breast cancer

Human Pathology

Volumn 38, Issue 8, 2007, Pages 1105-1122

  Lambros, Maryou B K ^a   Natrajan, Rachael ^a   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Chromogenic in situ hybridization; Fluorescent in situ hybridization; Molecular genetics

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CHROMOGENIC SUBSTRATE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLUOROCHROME; PROTEIN ESR1; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 12P; CHROMOSOME 16Q; CHROMOSOME 17Q; CHROMOSOME 20Q; CHROMOSOME 8P; CHROMOSOME TRANSLOCATION; CLINICAL PRACTICE; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC PROCEDURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DELETION; GENE TRANSLOCATION; GENOMIC IN SITU HYBRIDIZATION; HIGH THROUGHPUT SCREENING; HUMAN; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; METASTASIS; MICROARRAY ANALYSIS; ONCOGENE; ONCOGENE MYC; PROGNOSIS; REVIEW; TISSUE MICROARRAY; TOP2A GENE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CHROMOGENIC COMPOUNDS; DNA, NEOPLASM; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR DIAGNOSTIC TECHNIQUES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34447295638     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.04.011     Document Type: Review

References (183)

1. Simpson P.T., Reis-Filho J.S., Gale T., and Lakhani S.R. Molecular evolution of breast cancer. J Pathol 205 (2005) 248-254
2. Buerger H., Mommers E.C., Littmann R., et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 194 (2001) 165-170
3. Buerger H., Otterbach F., Simon R., et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 187 (1999) 396-402
4. Buerger H., Otterbach F., Simon R., et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 189 (1999) 521-526
5. Chin K., DeVries S., Fridlyand J., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 (2006) 529-541
6. Hwang E.S., DeVries S., Chew K.L., et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 10 (2004) 5160-5167
7. Jones C., Ford E., Gillett C., et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 10 (2004) 5988-5997
8. Roylance R., Gorman P., Harris W., et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 59 (1999) 1433-1436
9. Reis-Filho J.S., and Lakhani S.R. The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res 5 (2003) 313-319
10. Abdel-Fatah T.M., Powe D.G., Hodi Z., Lee A.H., Reis-Filho J.S., and Ellis I.O. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 31 (2007) 417-426
11. Reis-Filho J.S., Simpson P.T., Gale T., and Lakhani S.R. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol Res Pract 201 (2005) 713-725
12. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
13. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
14. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
15. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
16. Tutt A.N., Lord C.J., McCabe N., et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70 (2005) 139-148
17. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
18. Hicks D.G., and Tubbs R.R. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 36 (2005) 250-261
19. Tedesco K.L., Thor A.D., Johnson D.H., et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 22 (2004) 1071-1077
20. Burstein H.J., Harris L.N., Marcom P.K., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21 (2003) 2889-2895
21. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
22. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
23. Hicks J., Krasnitz A., Lakshmi B., et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 16 (2006) 1465-1479
24. Callagy G., Pharoah P., Chin S.F., et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 205 (2005) 388-396
25. Bartlett J.M. Fluorescence in situ hybridization: technical overview. Methods Mol Med 97 (2004) 77-87
26. Al-Kuraya K., Schraml P., Torhorst J., et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64 (2004) 8534-8540
27. Reis-Filho J.S., Savage K., Lambros M.B., et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 19 (2006) 999-1009
28. Prentice L.M., Shadeo A., Lestou V.S., et al. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene 24 (2005) 7281-7289
29. Gelsi-Boyer V., Orsetti B., Cervera N., et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res 3 (2005) 655-667
30. Makretsov N., He M., Hayes M., et al. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer 40 (2004) 152-157
31. Letessier A., Ginestier C., Charafe-Jauffret E., et al. ETV6 gene rearrangements in invasive breast carcinoma. Genes Chromosomes Cancer 44 (2005) 103-108
32. Rodriguez-Pinilla S.M., Jones R.L., Lambros M.B., et al. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol (2006)
33. Natrajan R., Reis-Filho J.S., Little S.E., et al. Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse. Cancer Res 66 (2006) 11148-11155
34. Lambros M.B., Simpson P.T., Jones C., et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 86 (2006) 398-408
35. Laakso M., Tanner M., and Isola J. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol 210 (2006) 3-9
36. Bartlett J.M., and Forsyth A. Detection of HER2 gene amplification by fluorescence in situ hybridization in breast cancer. Methods Mol Med 120 (2006) 309-322
37. Dowsett M., Bartlett J., Ellis I.O., et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199 (2003) 418-423
38. Ma Y., Lespagnard L., Durbecq V., et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11 (2005) 4393-4399
39. Mertens F., Johansson B., Hoglund M., and Mitelman F. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res 57 (1997) 2765-2780
40. Tubbs R.R., Pettay J.D., Swain E., et al. Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: a feasibility study. Appl Immunohistochem Mol Morphol 14 (2006) 436-440
41. Joshi A.S., Gholap A.S., van de Vijver M., Horlings H., and Kamble G. Automating chromogenic in situ hybridization interpretation for HER2/neu marker in breast carcinomas using cell recognition and color segmentation algorithms. Arch Pathol Lab Med 130 (2006) 1398 [poster 9]
42. van de Vijver M. Emerging technologies for HER2 testing. Oncology 63 Suppl 1 (2002) 33-38
43. Bhargava R., Gerald W.L., Li A.R., et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18 (2005) 1027-1033
44. Reis-Filho J.S., Pinheiro C., Lambros M.B., et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 209 (2006) 445-453
45. Reis-Filho J.S., Milanezi F., Carvalho S., et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 7 (2005) R1028-R1035
46. Reis-Filho J.S., Simpson P.T., Turner N.C., et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 12 (2006) 6652-6662
47. Garcia M.J., Pole J.C., Chin S.F., et al. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene 24 (2005) 5235-5245
48. Letessier A., Sircoulomb F., Ginestier C., et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6 (2006) 245
49. Rummukainen J.K., Salminen T., Lundin J., Joensuu H., and Isola J.J. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 81 (2001) 1545-1551
50. Courjal F., Cuny M., Simony-Lafontaine J., et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 57 (1997) 4360-4367
51. Cuny M., Kramar A., Courjal F., et al. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 60 (2000) 1077-1083
52. Barbareschi M., Pelosio P., Caffo O., et al. Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Int J Cancer 74 (1997) 171-174
53. Barnes D.M. Cyclin D1 in mammary carcinoma. J Pathol 181 (1997) 267-269
54. Jirstrom K., Stendahl M., Ryden L., et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 65 (2005) 8009-8016
55. Pelosio P., Barbareschi M., Bonoldi E., et al. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 7 (1996) 695-703
56. Schraml P., Kononen J., Bubendorf L., et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5 (1999) 1966-1975
57. Hughes-Davies L., Huntsman D., Ruas M., et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115 (2003) 523-535
58. Raouf A., Brown L., Vrcelj N., et al. Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. J Natl Cancer Inst 97 (2005) 1302-1306
59. Arriola E., Rodriguez-Pinilla S.M., Lambros M.B., et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat (2007) [epub ahead of print; doi:10.1007/s10549-006-9492-5]
60. Cardoso F., Durbecq V., Larsimont D., et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 24 (2004) 201-209
61. Durbecq V., Paesmans M., Cardoso F., et al. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 3 (2004) 1207-1214
62. Hicks D.G., Yoder B.J., Pettay J., et al. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol 36 (2005) 348-356
63. Theillet C., Adelaide J., Louason G., et al. FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer 7 (1993) 219-226
64. Huang H.E., Chin S.F., Ginestier C., et al. A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. Cancer Res 64 (2004) 6840-6844
65. Holst F., Stahl P.R., Ruiz C., et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39 (2007) 655-660
66. Bartlett J.M., Ibrahim M., Jasani B., et al. External quality assurance of HER2 FISH testing: results of a UK NEQAS pilot scheme. J Clin Pathol (2006) [epub ahead of print; doi:10.1136/jcp.2006.040840]
67. Ellis I.O., Bartlett J., Dowsett M., et al. Best practice no 176: updated recommendations for HER2 testing in the UK. J Clin Pathol 57 (2004) 233-237
68. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
69. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131 (2007) 18
70. Bilous M., Dowsett M., Hanna W., et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 16 (2003) 173-182
71. Dal Lago L., Durbecq V., Desmedt C., et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 5 (2006) 2572-2579
72. McCormick S.R., Lillemoe T.J., Beneke J., Schrauth J., and Reinartz J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 117 (2002) 935-943
73. Zhao J., Wu R., Au A., Marquez A., Yu Y., and Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 15 (2002) 657-665
74. Dandachi N., Dietze O., and Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 82 (2002) 1007-1014
75. Gupta D., Middleton L.P., Whitaker M.J., and Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 119 (2003) 381-387
76. Arnould L., Denoux Y., MacGrogan G., et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 88 (2003) 1587-1591
77. Diaz L.K., Gupta R., Kidwai N., Sneige N., and Wiley E.L. The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer. J Histochem Cytochem 52 (2004) 501-507
78. Denoux Y., Arnould L., Fiche M., et al. HER2 gene amplification assay: is CISH an alternative to FISH?. Ann Pathol 23 (2003) 617-622
79. Vera-Roman J.M., and Rubio-Martinez L.A. Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med 128 (2004) 627-633
80. Isola J., Tanner M., Forsyth A., Cooke T.G., Watters A.D., and Bartlett J.M. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 10 (2004) 4793-4798
81. Wixom C.R., Albers E.A., and Weidner N. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol 12 (2004) 248-251
82. Hauser-Kronberger C., and Dandachi N. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol 35 (2004) 647-653
83. Bhargava R., Lal P., and Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?. Am J Clin Pathol 123 (2005) 237-243
84. Gong Y., Gilcrease M., and Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol 18 (2005) 1015-1021
85. Loring P., Cummins R., O'Grady A., and Kay E.W. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl Immunohistochem Mol Morphol 13 (2005) 194-200
86. Li-Ning T.E., Ronchetti R., Torres-Cabala C., and Merino M.J. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. Int J Surg Pathol 13 (2005) 343-351
87. Hanna W.M., and Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 19 (2006) 481-487
88. Bilous M., Morey A., Armes J., Cummings M., and Francis G. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. Pathology 38 (2006) 120-124
89. Di Palma S., Collins N., Faulkes C., et al. Chromogenic in-situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. J Clin Pathol (2007) [epub ahead of print; doi:10.1136./jcp.2006.043356]
90. Ricardo S., Milanezi F., Carvalho S., Leitao D., and Schmitt F. HER2 evaluation through the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol (2006)
91. Leong A.S., Formby M., Haffajee Z., Clarke M., and Morey A. Refinement of immunohistologic parameters for Her2/neu scoring validation by FISH and CISH. Appl Immunohistochem Mol Morphol 14 (2006) 384-389
92. Merola R., Mottolese M., Orlandi G., et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer 42 (2006) 1501-1506
93. Vanden Bempt I., Vanhentenrijk V., Drijkoningen M., Wlodarska I., Vandenberghe P., and De Wolf-Peeters C. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology 46 (2005) 431-441
94. Salido M., Tusquets I., Corominas J.M., et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 7 (2005) R267-R273
95. Varshney D., Zhou Y.Y., Geller S.A., and Alsabeh R. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol 121 (2004) 70-77
96. Downs-Kelly E., Yoder B.J., Stoler M., et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 29 (2005) 1221-1227
97. Risio M., Casorzo L., Redana S., and Montemurro F. HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. Oncol Rep 13 (2005) 305-309
98. Di Leo A., and Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?. Clin Breast Cancer 4 (2003) 179-186
99. Jarvinen T.A., and Liu E.T. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 6 (2006) 579-602
100. Jarvinen T.A., and Liu E.T. HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 78 (2003) 299-311
101. Jarvinen T.A., Tanner M., Barlund M., Borg A., and Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26 (1999) 142-150
102. Durbecq V., Desmed C., Paesmans M., et al. Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol 25 (2004) 1473-1479
103. Tanner M., Jarvinen P., and Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 61 (2001) 5345-5348
104. Knoop A.S., Knudsen H., Balslev E., et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23 (2005) 7483-7490
105. Tanner M., Isola J., Wiklund T., et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24 (2006) 2428-2436
106. Hannemann J., Kristel P., van Tinteren H., et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 95 (2006) 1334-1341
107. Mueller R.E., Parkes R.K., Andrulis I., and O'Malley F.P. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 39 (2004) 288-297
108. Park K., Kim J., Lim S., and Han S. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39 (2003) 631-634
109. Slamon D., Eiermann W., Robert N., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC (R) T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC (R) TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94 Suppl (2005) S5
110. Jarvinen T.A., Tanner M., Rantanen V., et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156 (2000) 839-847
111. Jacobson K.K., Morrison L.E., Henderson B.T., et al. Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer 40 (2004) 19-31
112. Olsen K.E., Knudsen H., Rasmussen B.B., et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 43 (2004) 35-42
113. Park K., Han S., Gwak G.H., Kim H.J., Kim J., and Kim K.M. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat 98 (2006) 337-342
114. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
115. Haas-Kogan D.A., Prados M.D., Lamborn K.R., Tihan T., Berger M.S., and Stokoe D. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 4 (2005) 1369-1372
116. Bell D.W., Lynch T.J., Haserlat S.M., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23 (2005) 8081-8092
117. Tsuda H., Tani Y., Weisenberger J., et al. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with "stem-cell-like" features. Cancer Sci 96 (2005) 333-339
118. Laakso M., Tanner M., Nilsson J., et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 12 (2006) 4185-4191
119. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295 (2006) 2492-2502
120. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., and Ellis I.O. Prognostic markers in triple-negative breast cancer. Cancer 109 (2007) 25-32
121. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
122. Yehiely F., Moyano J.V., Evans J.R., Nielsen T.O., and Cryns V.L. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12 (2006) 537-544
123. Turner N.C., and Reis-Filho J.S. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25 (2006) 5846-5853
124. Lakhani S.R., Reis-Filho J.S., Fulford L., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11 (2005) 5175-5180
125. Corzo C., Tusquets I., Salido M., et al. Characterization of HER1 (c-erbB1) status in locally advanced breast cancer using fluorescence in situ hybridization and immunohistochemistry. Tumour Biol 26 (2005) 25-30
126. Kersting C., Tidow N., Schmidt H., et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 84 (2004) 582-587
127. Chitale D.A., Akram M., Brogi E., and Barbashina V. Epidermal growth factor receptor (EGFR) protein overexpression is associated with gene amplification in metaplastic carcinomas of the breast (MCB). Mod Pathol 19 Suppl 1 (2006) 23A
128. Rossi M.R., La Duca J., Matsui S., Nowak N.J., Hawthorn L., and Cowell J.K. Novel amplicons on the short arm of chromosome 7 identified using high resolution array CGH contain overexpressed genes in addition to EGFR in glioblastoma multiforme. Genes Chromosomes Cancer 44 (2005) 392-404
129. Kersting C., Kuijper A., Schmidt H., et al. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest 86 (2006) 54-61
130. Deming S.L., Nass S.J., Dickson R.B., and Trock B.J. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83 (2000) 1688-1695
131. Park K., Kwak K., Kim J., Lim S., and Han S. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol 36 (2005) 634-639
132. Kim C., Bryant J., Horne Z., et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Breast Cancer Res Treat 94 (2005) S6-S7
133. Palacios J., Honrado E., Cigudosa J.C., and Benitez J. ERBB2 and MYC alterations in BRCA1- and BRCA2-associated cancers. Genes Chromosomes Cancer 42 (2005) 204-205 [author reply 206]
134. Grushko T.A., Dignam J.J., Das S., et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 10 (2004) 499-507
135. Robanus-Maandag E.C., Bosch C.A., Kristel P.M., et al. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol 201 (2003) 75-82
136. Reis-Filho J.S., Simpson P.T., Jones C., et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 207 (2005) 1-13
137. Aulmann S., Bentz M., and Sinn H.P. C-myc oncogene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 74 (2002) 25-31
138. Fiche M., Avet-Loiseau H., Maugard C.M., et al. Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: relation to morphology, cell proliferation and expression of breast cancer-related genes. Int J Cancer 89 (2000) 403-410
139. Vos C.B., ter Haar N.T., Rosenberg C., et al. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer 81 (1999) 1410-1418
140. Seshadri R., Lee C.S., Hui R., McCaul K., Horsfall D.J., and Sutherland R.L. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 2 (1996) 1177-1184
141. Vaziri S.A., Tubbs R.R., Darlington G., and Casey G. Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol 54 (2001) 259-263
142. Bieche I., Olivi M., Nogues C., Vidaud M., and Lidereau R. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 86 (2002) 580-586
143. Bekri S., Adelaide J., Merscher S., et al. Detailed map of a region commonly amplified at 11q13?q14 in human breast carcinoma. Cytogenet Cell Genet 79 (1997) 125-131
144. Janssen J.W., Cuny M., Orsetti B., et al. MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer. Int J Cancer 102 (2002) 608-614
145. Rodriguez C., Hughes-Davies L., Valles H., et al. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 10 (2004) 5785-5791
146. Lafage M., Pedeutour F., Marchetto S., et al. Fusion and amplification of two originally non-syntenic chromosomal regions in a mammary carcinoma cell line. Genes Chromosomes Cancer 5 (1992) 40-49
147. Pole J.C., Courtay-Cahen C., Garcia M.J., et al. High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene 25 (2006) 5693-5706
148. Bautista S., and Theillet C. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei. Genes Chromosomes Cancer 22 (1998) 268-277
149. Elsheikh S.E., Green A.R., Lambros M.B.K., et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 9 (2007) R23
150. Moore E., Magee H., Coyne J., Gorey T., and Dervan P.A. Widespread chromosomal abnormalities in high-grade ductal carcinoma in situ of the breast. Comparative genomic hybridization study of pure high-grade DCIS. J Pathol 187 (1999) 403-409
151. Tanner M.M., Tirkkonen M., Kallioniemi A., et al. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res 56 (1996) 3441-3445
152. Tanner M.M., Tirkkonen M., Kallioniemi A., et al. Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res 54 (1994) 4257-4260
153. Tanner M.M., Tirkkonen M., Kallioniemi A., et al. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1 (1995) 1455-1461
154. Ginestier C., Cervera N., Finetti P., et al. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 12 (2006) 4533-4544
155. Kallioniemi A., Kallioniemi O.P., Piper J., et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci U S A 91 (1994) 2156-2160
156. Heidenblad M., Lindgren D., Veltman J.A., et al. Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications. Oncogene 24 (2005) 1794-1801
157. Heidenblad M., Schoenmakers E.F., Jonson T., et al. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res 64 (2004) 3052-3059
158. Solinas-Toldo S., Wallrapp C., Muller-Pillasch F., Bentz M., Gress T., and Lichter P. Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res 56 (1996) 3803-3807
159. Pierga J.Y., Reis-Filho J.S., Cleator S.J., et al. Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer 96 (2007) 341-351
160. Neve R.M., Chin K., Fridlyand J., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10 (2006) 515-527
161. Wong K.K., deLeeuw R.J., Dosanjh N.S., et al. A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet 80 (2007) 91-104
162. Tognon C., Knezevich S.R., Huntsman D., et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2 (2002) 367-376
163. Diallo R., Tognon C., Knezevich S.R., Sorensen P., and Poremba C. Secretory carcinoma of the breast: a genetically defined carcinoma entity. Verh Dtsch Ges Pathol 87 (2003) 193-203
164. Simpson P.T., Gale T., Reis-Filho J.S., et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol 29 (2005) 734-746
165. Cleton-Jansen A.M., Buerger H., Haar N., et al. Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer 41 (2004) 109-116
166. Tsuda H., Takarabe T., Akashi-Tanaka S., Fukutomi T., and Hirohashi S. Pattern of chromosome 16q loss differs between an atypical proliferative lesion and an intraductal or invasive ductal carcinoma occurring subsequently in the same area of the breast. Mod Pathol 14 (2001) 382-388
167. Tsuda H., Takarabe T., Fukutomi T., and Hirohashi S. Preferential occurrence of breast carcinomas with loss of chromosome 16q and der (16) t (1;16) / der (1;16) in middle-aged patients with hyperplasia of mammary glands. Jpn J Cancer Res 91 (2000) 692-699
168. Tsuda H., Takarabe T., and Hirohashi S. Correlation of numerical and structural status of chromosome 16 with histological type and grade of non-invasive and invasive breast carcinomas. Int J Cancer 84 (1999) 381-387
169. Flagiello D., Gerbault-Seureau M., Sastre-Garau X., Padoy E., Vielh P., and Dutrillaux B. Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer 23 (1998) 300-306
170. Futreal P.A., Liu Q., Shattuck-Eidens D., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 (1994) 120-122
171. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
172. Gudmundsdottir K., and Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25 (2006) 5864-5874
173. Turner N., Tutt A., and Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 4 (2004) 814-819
174. Xu C.F., and Solomon E. Mutations of the BRCA1 gene in human cancer. Semin Cancer Biol 7 (1996) 33-40
175. Turner N.C., Reis-Filho J.S., Russell A.M., et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26 (2007) 2126-2132
176. Birgisdottir V., Stefansson O.A., Bodvarsdottir S.K., Hilmarsdottir H., Jonasson J.G., and Eyfjord J.E. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 8 (2006) R38
177. Wei M., Grushko T.A., Dignam J., et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 65 (2005) 10692-10699
178. Catteau A., Harris W.H., Xu C.F., and Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18 (1999) 1957-1965
179. Bell D.W., Erban J., Sgroi D.C., and Haber D.A. Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. Cancer Res 62 (2002) 2741-2743
180. Merajver S.D., Frank T.S., Xu J., et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res 1 (1995) 539-544
181. Staff S., Isola J.J., Johannsson O., Borg A., and Tanner M.M. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa. Br J Cancer 85 (2001) 1201-1205
182. Staff S., Nupponen N.N., Borg A., Isola J.J., and Tanner M.M. Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers. Genes Chromosomes Cancer 28 (2000) 432-442
183. Lancaster J.M., Wooster R., Mangion J., et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13 (1996) 238-240